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ABSTRACT
Organ transplantation has made great progress since the first successful
kidney transplant in 1953 and now more than one million tissue transplants are
performed in the United States every year (www.organdonor.gov/statisticsstories, 2015). However, the hope and success of organ transplants are often
overshadowed by their reputation as being notoriously difficult to procure
because of donor-recipient matching and availability. In addition, those that are
fortunate enough to receive a transplant are burdened with a lifetime of
immunosuppressants. The field of regenerative medicine is currently making
exceptional progress toward making it possible for a patient to be their own
donor. Cells from a patient can be collected, reprogrammed into stem cells, and
then differentiated into specific cell types. This technology combined with recent
advances in 3D printing provides a unique opportunity. Cells can now be
accurately deposited with computerized precision allowing tissue engineering
from the inside out (Gill, 2016). However, more work needs to be done as these
techniques have yet to be perfected. Bioprinters can cost hundreds of thousands
of dollars, and the bioink they consume costs thousands per liter. The resulting
cost in development of protocols required for effective tissue printing can thus be
cost-prohibitive, limiting the research to labs which can afford this exorbitant cost
and in turn slowing the progress made in the eventual creation of patient derived
stem cell engineered organs.
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The objective of my research is to develop a simple and low-cost
introductory system for biological additive manufacturing (Otherwise known as
3D bioprinting). To create an easily accessible and cost-effective system several
design constraints were implemented. First, the system had to use mechanical
components that could be purchased “off-the-shelf” from commonly available
retailers. Second, any mechanical components involved had to be easily
sterilizable, modifiable, and compatible with open-source software. Third, any
customized components had to be fabricated using only 3D printing and basic
tools (i.e. saw, screwdriver, and wrench). Fourth, the system and any expendable
materials should be financially available to underfunded school labs, in addition
to being sterilizable, biocompatible, customizable, and biodegradable. Finally, all
hardware and expendables had to be simple enough as to be operated by high
school science students.
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CHAPTER ONE
THE NEED FOR 3D PRINTED TISSUES

Tissue Transplant
The earliest crude examples of tissue transplants utilized xenografts.
Tissue, commonly animal hide, would be grafted onto a patient who suffered
deep and extensive tissue damage. Later, human cadaver tissue would be used
in place of animal hide. This alternative practice is still common, as many
transplanted tissues are typically sourced from organ donors. Animal tissues are
finding their way back into medicine through xenotransplantation, with the
development of immune compatible chimera organs, decellularized animal organ
scaffolds, reseeded with patient derived stem cells.
While promising, these methods still have drawbacks. In the case of
human organ donor-sourced transplants there remains an insufficient supply of
donors to meet the demand for tissues (Figure 1). Although animal derived
tissues may provide a solution to the high demand, they also come with their own
set of problems which include differences in morphology, greater risk of rejection,
and availability (Watson, 2011). Even with chimeras or with decellularization and
reseeding methods, patient rejection of the tissue is still a possibility. Both
methods would likely fall short of meeting current demand or remaining costeffective, making their ability to replace or supplement current transplant
methods unlikely.
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Figure 1: Global Organ Transplant Shortage.
Cell Culture: Then and Now
In 1907 Ross Harrison developed the first protocol for first 3D cell culture
and was able to cultivate cells via the Hanging Drop method (Harrison, 1910). In
1916, Peyton Rous and F.S Jones developed a technique for removing adherent
cells via trypsin enzyme. In 1948, Earle was able to isolate the first fibroblast cell
lines. The first chemically defined media was developed in 1955 by Harry Eagle
and is still in wide use today. This project uses a variant of the original Eagle
Medium known as Dulbecco’s Modiﬁed Eagle's Medium (DMEM). In 1962, Dr.
George Todaro and Dr. Howard Green developed the 3T3, or three-day transfer,
mouse fibroblast cell line which is now considered the standard fibroblast line.
(www.nih3t3.com, 2017). Isolation of the first pluripotent stem cell lines can be
credited to Martin Evans and Gail Martin, who in 1981 successfully derived
pluripotent stem cells from mouse embryos (MESC). Embryonic stem cell lines
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yielded many advancements in the field of medicine however were subject to
controversy ultimately research was subsequently restricted in 2001 by the Bush
administration. In 2006, Dr. Shinya Yamanaka and his team were able to induce
successful pluripotency in mouse cells, creating the first induced pluripotent stem
cells (iPSCs). The benefit of iPSCs is that they are easily obtainable terminally
differentiated cell samples which can be reprogrammed back into a stem-like
state and then differentiated toward a specific lineage. This method when
combined with 3D printing certainly has the potential in the clinical setting to
produce patient-compatible tissue constructs.
Researchers have clearly made huge advances in cell culture; There
remains two major hurdles in the clinical applications of cell culture. The first is
the difficulty of culturing large quantities of stem cells suitable for use in
treatments. Currently cell sorting and bioreactors seem to be the most promising
technologies to overcome this obstacle (Mironov, 2011). The second obstacle is
controlled differentiation. Controlled differentiation requires manipulation of the
intracellular and extracellular chemical environments over time, as well as the
mechanical microenvironments. 3D printing technology has the potential to
resolve these issues, as chemical and mechanical gradients can be introduced
into the construct’s design. This would emulate the natural environmental signals
that normally guide stem cell differentiation in vivo.

Additive Manufacturing (3D Printing)

3

The earliest roots of modern 3D printing date back to the 1950s with the
advent of inkjet printing systems. The first patent for a 3D printing system was
filed in 1984 by Charles Hull. The system used a vat of UV sensitive
photopolymer with a Z-axis platform; a UV laser activates a photo initiator that in
turn crosslinks molecules in polystyrene resin. This occurs layer-by-layer as the
Z-axis platform submerges into the vat (www.3dsystems.com/our-story, 2017).
The systems were expensive, unreliable, and time-consuming, but could convert
a 3D computer model into a physical model overnight. The process was named
Stereolithography, or SL[A]. Charles Hull went on to launch one of the first major
manufacturers of today’s 3D printers, 3D Systems.
In 1986, Scott Crump developed a method called fused deposition
modeling (FDM), using a modified hot glue gun to extrude molten plastic
(Horvath, 2014). This system proved to be the forbearer of most 3D printers to
come. In FDM, molten plastic is extruded from a heated tip mounted to an XYZ
platform, allowing it to create 3D objects. Crump went on to launch Stratasys
Systems, the largest 3D printer manufacturer today (Savini, 2015).
In 2005, Adrian Bowyer founded the Replication Rapid Prototyper
(RepRap) project. His goal was to develop an open-source 3D printing system
capable of self-replication. Project RepRap went on to birth the modern home 3D
printing industry, as it allowed for low-cost printers to be built at home. One of its
descendants, MakerBot, has become the gold standard of affordable home 3D
printers. The RepRap project made use of Arduino modular computers and FDM
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printing techniques to make 3D printing an affordable alternative to traditional
subtractive manufacturing. Presently, 3D printers are no longer limited to plastics
-- they can print glass, metal, sugar, clay, and even cell-infused gels for
bioprinting applications (Goldberg, 2017).

3D Bioprinting
Bioprinting is at the cutting edge
of engineering and biology. The process
combines Computer Aided Drafting
(CAD), additive manufacturing (3D
printing), and tissue culture to produce
living, three-dimensional structures. The
history of bioprinting is relatively short.
In 1999, Dr. Anthony Atala successfully

Figure 2: NovoGen MMX.

used a 3D printer to print scaffolds.
These scaffolds were seeded with living cells, creating an artificially engineered
bladder. Later in 2003, Thomas Boland developed the first method for modifying
an inkjet printer for cell distribution (Murphy, 2014). In 2009, the company
Organovo began development of the NovoGen MMX Bioprinter (Figure 2), one of
the first purpose-built bioprinters. The same year, researchers at Organovo
successfully integrated vasculature into printed structures. This advancement
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was important as media diffusion limits the thickness and size of bio printed
constructs (www.organovo.com/about/history/, 2017).
The issues of controlled cell
differentiation and large-scale proliferation are
not the only things limiting the clinical
applicability of cell culture. Equipment costs are
another obstacle because purpose-built
bioprinters are exceedingly expensive, often
costing in the six-figure range. In 2015, a
startup company called BioBots rolled out the
BioBot 1, the first purpose-built bioprinter based
on technology developed for low-cost desktop

Figure 3: SE3D Rebel Mini.

3D printers, but even this system retails for
$10,000 (www.biobots.io/, 2017). As of 2018, the bioprinter market has grown
extensively as several commercially available bioprinters exist with the cheapest
being the direct injection Rebel Series by SE3D for $4,000 (Figure 3)
(https://www.se3d.com/,2018).
The objective of this research is to develop a bioprinting process using a
common, low-cost, 3D printer modified with 3D printed, and store-purchased
components. Any printer modifications made must also be simple enough that a
person with no technical experience can perform them. The bioink used in this
process will allow for cost-effective bioprinting optimization. By reducing the
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hardware, and overhead costs of this technology I hope to make it available to
Biology students at the high school and college level. Providing introductory
students meaningful STEM research experience.
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CHAPTER TWO
MATERIALS AND METHODS

3D Printer Modification
The printer chosen for this project was the Creator Pro dual-head desktop
3D printer by FlashForge. This printer was chosen for several reasons. The
printer is one of the lowest-cost dual head printers on the market. This fulfilled
one of the primary goals of the project as the unit cost was under $1,000. The
benefit of having a dual head printer instead of a single head printer was that not
only could the printer print using two different materials simultaneously without
the need to switch syringes, but the printhead carriage and supporting XYZ drive
system was larger and more robust. A major office supply retailer carries this
product in store, thus fulfilling the goal of being easily obtainable as the machine
could be picked up locally without pre-order and added shipping costs. The
printer itself was already fully assembled out-of-the-box and is known as a
MakerBot clone. MakerBot is currently the most popular model of home desktop
3D printers. MakerBot clones can make use of some of the MakerBot legacy
software and hardware options. Overall this compatibility helps the printer meet
the third and most important goal of easy modifiability. The Creator Pro was also
chosen over lower-cost machines as it was fully enclosed with a steel frame and
has a full, removable, external enclosure -- thus making sterilization easy and the
steel frame providing more structural integrity (www.flashforge-usa.com/creatorpro, 2017).
8

The printer is nearly fully assembled out-of-the-box, requiring only the
addition of screw-on filament spools that contain the ABS printing plastic. This
model printer also comes fully enclosed with a removable plastic shell, which
could potentially be modified to act as a sterile cabinet, although for the purposes
of this project these outer panels were removed. Removal of the outer panels
was relatively straightforward as the printer comes with the necessary wrenches
to remove any of the screws. Once the outer panels were removed, the printhead
assembly then had to be unscrewed, and the filament extrusion motors as well
as thermal sensors had to be unscrewed from the printhead assembly. The
extrusion heads, heatsinks, and cooling fans, as well as printhead chassis, were
then discarded. The thermal sensors and unneeded wiring were then detached
from the harness and conduit tube. The sensors were screwed into an unused
socket and the excess wiring was then coiled up and zip-tied under the printer
XYZ chassis. The conduit tube was then removed to help mitigate the possibility
of sterilization issues. The X-axis touch sensors were removed from their clip-on
housings and secured via hot glue to a thin 2 cm x 3 cm ABS card. This card was
then slid back into the clip effectively extending the touch sensor beyond the XYZ
chassis frame and preventing the bio printhead from contacting the chassis
frame. This modification was later reversed after the integration of an extended
contact bracket on the PSP2-B and later bio printhead variants. Lastly, the build
platform was dropped approximately 5 mm via the lowering wingnuts, which are
typically used to level the platform during initial setup. This adjustment allowed
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Figure 4: Creator Pro 3D Printer.
the printhead to have a longer extrusion tip as well as provided room for
the petri dish bottom (Figure 4).

Development of 3D Printable Syringe Pump Printhead
Typically, commercially built bioprinters use a pneumatic system to
dispense bioink material. Due to the difficulty of developing a low-cost or easily
constructed pneumatic delivery system, a screw driven bioink delivery system
was given consideration. Screw drives are more precise and reliable than
pneumatic systems, hence their heavy use in traditional 3D printing. However,
screw drives have less pressure control and as such may cause additional shear
forces on the embedded cells (Malda, 2013).
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Initial development was relatively straightforward. Measurements were
taken of the original printhead assembly, taking careful note of the size
limitations, as well as the mounting points and center points for the original
extruders. A single-piece 3D printable syringe pump was designed (PSP1). The
PSP1 (Figure 5) was a dual-head extruder that utilized two linear actuator fivephase stepper motors. These motors were ordered from www.sparkfun.com.
These motors drive a 20 cm threaded rod through the core of the stepper motor
with the intention of putting force on the plunger of inserted disposable 5 ml
syringes. The PSP1 was designed to occupy the same position as the original 3D
printhead, using the same mounting points
and hardware. The PSP1 accommodates both
2 mL and 5 mL syringes, with grooves and
notches placed to secure firmly the syringe in
place at precisely the center point of the
original extrusion head. Mounting points were
also designed into the PSP1 to allow for the
linear actuators to be easily mounted above
the syringe plungers.
Issues with the PSP1 were apparent
rather quickly. First, the design required the
use of support material that did not come with
the 3D printer. Second, measurements used
Figure 5: Printed Syringe Pump.
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in the design did not consider a notch in the XYZ carriage, which resulted in the
syringe pump needing to be trimmed down via a rotary tool by Dremel to fit into
the carriage. Third, the force required to compress a gel-loaded syringe was
more than the linear actuator could supply. The syringe pump was also heavy
even after having been printed using a honeycomb or “low infill” setting plus a
large internal cavity. The syringe fitting was also unsatisfactory as it was difficult
to load and unload syringes without risking tip contamination.

The PSP2
The PSP2 was designed in response to these challenges. The PSP2 was
significantly reduced in material and designed with flat printing surfaces in mind,
thus removing the need for printing of support material. The PSP2 (Figure 7) also

Figure 6: Flashprint Software Adjustments.
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better considered the profile of the original printhead, allowing a snug fit into the
XYZ carriage while using the original attachment points. Instead of a direct
compression system, a screw drive system was used, similar to how
conventional syringe pumps operate. A 10 mm, metric-threaded steel rod was
purchased from Home Depot along with 10 mm hex nuts. The five-phase stepper
motors from the original 3D printhead were salvaged and mounted via designed
attachment points to the bio printhead. Steel couplings also purchased from
Home Depot were used to join the shaft of
the stepper motor to the threaded rod. 3D
printed compression plates were designed to
slip over the hex nut and threaded rod and
ride on a pair of 10 cm ¼-inch aluminum
rods. These rods were also purchased from
Home Depot and hacksawed to size just as
the threaded rod was. The PSP2 was then
able to be secured into the XYZ carriage,
and the stepper motors could be
reconnected to the 3D printer control board.
The syringe ports were made to fit only 5 mL
syringes, with a larger lower opening still
centered where the original extruder was but
Figure 7: Printed Syringe Pump 2.
able to be easily loaded and unloaded
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without risking contamination. Subsequent testing of the PSP2 revealed two
major design issues. One, the printhead was top-heavy and prone to print tip
vibration during the printing process. This instability resulted in substantial loss of
print quality. Only rough test-prints could be created as the printhead vibration
caused bioink layer deposition inconsistency and subsequent layer delamination.
Two, the printhead extrusion mechanism, or a combination of both the printhead
extrusion tip and the syringe pump compression mechanism, suffered decreased
print resolution. Stepper motors driving the syringe pump had difficulty driving the
threaded syringe compression rod as bioink had to be of firm gelatinous viscosity
to achieve usable print quality. The printhead extrusion tip itself also needed to
be of high gauge in order to maintain print resolution, although the 26-gauge
resolution of the original plastic extrusion printer hardware could not be matched
as driving the bioink through this gauge was not possible at the required
viscosity. These issues were addressed in variants of the PSP2 printhead
design.
PSP2-A attempted to correct for this printhead instability by reinforcing the
lower portion of the printhead with additional material laterally along the printhead
interfaces to resist X-axis movement forces as well as by introducing a forward
strut to resist Y-axis movement. These modifications combined with the
replacement of the standard-thread compression drive rods with fine metricthread drive rods resulted in negligible improvement in print quality as testing
revealed the guide rods and rocking of the printhead mount itself were causing
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much of the printhead instability. Software settings were adjusted in attempt to
compensate for the printhead instability by reducing the printhead travel speed
by 90% (Figure 6). However, this adjustment still yielded unsuitable test prints as
well as further worsening the issue with bioink extrusion quality as the gel would
become too viscous for extrusion during the printing process, resulting in
unstable bioink flow and frequent tip blockages.
The PSP2-B (Figure 8) was redeveloped in attempt to further mitigate the
previously mentioned issues. The most notable modification to the printhead was
the use of zigzag supports in place of the solid 15% infill honeycomb lower
printhead attachment. This change was done to reduce overall material weight
without sacrificing structural integrity. The decreased weight would presumably
reduce the strain of the print
sled and XY bearings.
Additionally, a 4 mm
extension of the sled

PSP1
PSP2

PSP2-B

mounting surface of the
L-bracket X-axis
contact.

PSP2-B provides greater
support, as earlier printhead

PSP2-A

variants had a notable
wobble in the Y direction,

Zigzag support.

which could presumably be

Sled mounting
surface extension.

mitigated using an
Figure 8: PSP1, PSP2, PSP2-A, PSP2-B.
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additional supporting lip, thus allowing the printhead to be better supported on
the XY shelf. Beyond these stability enhancements, the PSP2-B was given an Lbracket protrusion on its lower-right surface and a reduced mid-section cross
plate. These modifications allowed the PSP2-B to make contact with the X-axis
positional switch without the need for additional modification of the 3D printer’s
existing X-axis switch as was required in earlier printhead variants. The midsection cross plate reduction was an attempt to minimize the overall printhead
weight as well as to minimize any accidental contact contamination during
syringe loading. Ultimately the reduced weight and stability enhancements did
not prove to be sufficient to stabilize the printhead nor to provide notable
improvement in the print quality.

The PSP3
The PSP3 (Figure 9) was designed to eliminate the top-heavy instability of
previous printhead designs. The direct injection method was abandoned after
over a year of development ultimately because it was not feasible with the
current hardware. Keeping this method would have required significant
modification of the 3D printer XY chassis yet still would likely have problems with
vibration in the XY axis print sled bearings. Additional likely problems might
include flexing in the steel guide rods as a result of the bio printhead’s large
stepper motors’ being mounted to the top of the syringe pump assembly,
resulting in instability and poor print quality. Even with software modifications
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Print chassis-mounted syringe
pump.

Plunger compression plate.
Syringe pump overhang.

L-bracket X-axis
contact.
Printer chassis
mounting groove.
Printhead barrel extension Lure lock interface.

Lure lock securing V groove-clip.

Figure 9: Printed Syringe Pump 3.

involving 90% reduced printhead travel speeds, test prints of simple circles were
of insufficient resolution (Figure 6).
In the end, the PSP3 was designed with two components: a print chassis-mounted syringe pump and an XY sled--printhead syringe mount. The two
components were based on earlier variants of the PSP2 designs, divided into two
halves with the syringe pump mechanism being heavily conserved in the
redesign and the stepper motor mounting plate being extended with additional
mounting holes added to secure this component to the chassis. The second
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component was created using the PSP2’s print chassis mounting plate and Lbracket X-axis contact. Additional modifications were included to provide luer
lock connections for printhead tip stability as syringes were no longer directly
mounted to the printhead, thus necessitating greater reinforcement to maintain
tip stability.
This configuration puts the bulk of the printhead’s weight (i.e. syringe
pump mechanism and stepper motors) onto the printer chassis, making use of
mounting points formerly used by cable guides in the printer’s factory hardware
setup. Screws were also repurposed to secure the syringe pump to the chassis.
The printhead sled was designed to make use of the luer lock groove profile to
provide additional support for the printhead itself while utilizing the PSP2-B’s XY
sled mounting profile and a modified X-axis contact switch--extension concept.
Initially the extruded bioink from the syringe pump was carried through
prepackaged sterile disposable IV extensions. These were hoped to minimize the
cost and steps of sterilization required for bioprinting. However, the high gauge
tubing and integrated valves used to prevent embolism created a bottleneck in
the bioink injector flow. This bottleneck impeded bioink flow to the point where
bioink of printable viscosity could not be extruded with the existing stepper
motors. Ultimately, traditional, inexpensive polyvinyl ⅛-inch tubing combined with
inexpensive, sterilizable, barbed, acrylic, male and female luer lock connectors
provided a more stable bioink flow at the cost of additional sterilization steps.
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The printhead component, while being highly conserved from the PSP2
models, was modified to have a barrel extension with V groove slots matching
the luer lock connectors on the surgical tubing. This change allows a 3D printed
V clip to be placed in the slot for improved syringe tip stability. Moreover, this
design offers locking in the surgical tubing with a barbed acrylic luer lock, thus
decreasing the likelihood of connection failure from positional strain on the
tubing. Ultimately test prints with the PSP3 demonstrated the stability required for
higher resolution bio printed constructs to be generated.

Initial Testing of PSP2 and PSP3
Initial tests as with the PSP2s focused on printing 1 cm rings (Figure 6),
chosen for their ready ability to create simple, structurally sound shapes, in
addition to their proclivity in cell culture tests for ready media diffusion into
cultured cells. 120 mm polystyrene petri dishes were used to provide a
removable, sterile build surface. The petri dish lid was affixed to the printer build
platform with the application of a few drops of bioink as the capillary action
between the build surface and petri dish secured the lid in place. The build
surface was then manually adjusted on Z-axes to compensate for the thickness
of the petri dish. With several rings printing successfully, a more complex final
test print was chosen. The complex shape of a human ear was selected as its
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thin structures would still provide media
diffusion while at the same time
demonstrating the bioprinter’s resolution
potential and outlining a shape which
envisions the system’s biomedical
possibilities.
As when doing the ring prints, the
PSP3’s reduced load on the print chassis

Figure 10: Human Ear Construct.

sled, without the weight of the stepper
motors, was able to move at a rapid pace with no notable speed wobble. Due to
this improved printhead stability, the print speed (i.e. bioink deposition) did not
require adjustment from machine factory settings. This rate allowed for small
complex structures such as the human ear (Figure 10) to be fabricated in bioink,
in 40-50 minutes. A few additional adjustments were required for the larger
printed construct of the ear, primarily the 120 mm polystyrene petri dish lid that
served as the build surface. This lid had to be scored repeatedly in a hashed
pattern (Figure 10) with a sterile spatula to provide additional friction for the
larger, more complex structures to adhere as not scoring it would cause sections
of the initial print to detach, producing overall construct deformity.
Additional user interaction was required during test prints as the print
platform required occasional leveling adjustments every 3 mm or so in the
vertical axis to compensate for increased bioink deposition when compared to
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the printer’s original plastic deposition. This issue was discovered early on. As
the print increased in height, vertical adjustments were required to maintain
resolution and to prevent the printhead from contacting and disturbing the
previously deposited bioink layers. Manual adjustment was required as the bioink
deposition flattening, and temporal curing profile vary with the viscosity of the
bioink.

Gelatin Bioink Development
Several different options were considered for the formulation of a bioink.
One commercially available bioink distributed by BioBots is a proprietary blend
based primarily on Poly (lactic-co-glycolic acid), or PLGA. Unfortunately, this
synthetic, biocompatible and biodegradable polymer is also $200 per gram
(www.biobots.io/, 2017). Other, more conventional tissue engineering materials
such as Thermo Fisher's Geltrex or Corning's Matrigel require high
concentrations for 3D cell culture and average around $50 per mL. Ultimately a
gelatin-based bioink was selected as the most cost-effective candidate that was
both highly biocompatible and mechanically suitable for use as a bioink. Gelatin
when combined with the enzyme microbial transglutaminase MTGase creates a
hydrogel that congeals at 37 °C. The resulting bioink costs less than $1 per mL
(Zhao, 2016).
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The gelatin first used was Gibco type B bovine gelatin as bovine gelatin is
commonly available, and is the lowest cost. A 2% gelatin dissolved in 10%
phosphate buffered solution was created. This mixture was then autoclaved for

Table 1: Bovine Based Bioink Concentration Optimization.
Temp

MTG 5 mg/mL

MTG 15 mg/mL

MTG 30 mg/mL

MTG 60 mg/mL

23°C

Unstable

Unstable

Unstable

Unstable

37°C

Unstable

Gel

Gel

Gel

60°C

Denatured

Denatured

Denatured

Denatured

30 minutes at 121 °C and allowed to cool to room temperature. MTGase
(MooGloo RM) was purchased from Amazon.com. Several different
concentrations were tested, including 5 mg/mL, 15 mg/mL, 30 mg/mL, and 60
mg/mL. These concentrations were then dissolved into the gelatin solution and
incubated at 23 °C, 37 °C, and 60 °C. Concentrations of 15 mg/mL and 30
mg/mL were selected since lower concentrations
produced gels with low viscosities. 60 mg/mL
concentrations appeared to have similar
properties to the 15 mg/mL and 30 mg/mL
concentrations. Both refrigerated and 37 °C
incubations produced gels, but 60 °C incubation
appeared to denature the enzyme (Table 1).
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Figure 11: Bovine Gelatin
Type B Bioink.

Successful gels were then soaked in PBS
over 72 hours to confirm they did not
dissolve (Figure 11). Unfortunately, when
the experiment was repeated with gels
being submerged in DMEM culture media,
the gel dissolved. Both integration into
uncongealed gel, as well as submersion of
completed gel, showed the same results.

Figure 12: Gram Positive Bacilli
Bacterial Contamination.

After further literature review, type B
gelatin was found to have been processed using a different technique which
resulted in chemical differences making it unsuitable for cell culture.
Corning type A porcine gelatin was then selected. Concentration
optimization was repeated with the porcine gelatin with similar results. Ultimately
15 mg/mL and 30 mg/mL MTGase and 2% porcine type A 10% PBS solutions
were shown to survive submersion in DMEM for 72 hours under 37 °C. Even
after gel solution autoclave and careful sterile practices with the enzyme,
bacterial contamination was quickly and consistently found present (Figure 12).
Autoclaving the completed bioink was impossible as earlier experiments
and literature showed that MTGase would denature around 60 °C (Chen, 2014).
A second supply of MooGloo was purchased with the same result. The enzyme
was suggested to be dissolved into PBS and purified by filter sterilization.
Unfortunately, MTGase proved to be too difficult to filter sterilize directly, as it
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was too thick. Ultraviolet sterilization using a UV crosslinker at exposures of 10,
20, and 30 minutes was tested, but the contamination persisted. Several prefilters were used from 40 μm, 2 μm, 0.45 μm, to 0.22 μm, which resulted in a
significant loss of the initial solution. The MTGase solution was then centrifuged
as a pre-filtration step. Centrifuge speeds of 5,000 RPM for 5, 10, and 15
minutes were tested, however, this did not result in a filterable solution. A
centrifuge speed of 9,500 RPM for 20 minutes resulted in an MTGase solution
that could be effectively filter sterilized with a 0.22 μm syringe filter.
Later bioink cost optimizations found that 3,000 RPM centrifugation for 60
minutes provided a supernatant that was filter sterilizable at speeds that could be
obtained using conventional low-cost desktop centrifuges. In addition to cost
optimizing MTGase filter sterilization, porcine gelatin sterilization was also cost
optimized as 60 °C for 60 minutes of hot plate gel dissolution combined with filter
sterilization, proving to be as effective as the previous autoclaving protocol and
ultimately eliminating the need for laboratory autoclaving altogether. This finding
further highlights the financial feasibility of this bioink for under-funded and or
under-equipped laboratory facilities. The centrifuged MTGase solution and
porcine gelatin solution were filter sterilized in hood.
The final developed bioink loading protocol required immediate filter
sterilization of the gelatin into a 12 mL sterile conical tube. Any delay increased
gel viscosity inhibiting filtration. Next the MTGase supernatant was syringe filter
sterilized directly into the filtered bioink. The bioink was then agitated via pipette
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to intermix, and 9 mL of bioink was
then transferred into 1 mL of cellladen DMEM. The result was then
agitated via pipette, and then 10 mL
of the resulting cell-laden bioink was
pipetted into a sterile 10 mL syringe.
The syringe was then lure-locked to
the sterile syringe tip and ⅛-inch
tubing assembly and was

Figure 13: 3T3 Cells Cultured in Bioink.

compressed to remove any remaining inline DMEM used previously to flush the
print tip assembly. The bioink was left to congeal to a viscosity where syringe air
bubbles could not migrate when the syringe was inverted.
In the following phase, cells were cultured and transferred into the 15
mg/mL and 30 mg/mL concentration gels to investigate visually any possible
cytotoxic effects of the enzyme. The gels were created and transferred into
Corning culturing flasks with NIH3T3 cells. After six days there was no observed
change in cell morphology in either of the two concentration groups (Nguyen,
2017). This experiment was repeated with cells that were freshly seeded into the
flasks. The cells again showed no differences in morphology. Additionally, there
were no observed differences in either cell adhesion or time to confluency. The
3T3 cells adhered to both the surface of the gel fragments as well as the culture
flask (Figure 13). Next, 15 mg/mL and 30 mg/mL bioinks were produced. Bioinks
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were allowed to incubate for 3 hours prior to cell introduction. Cells were
detached from flasks by using 1 mL 1% trypsin for 30 seconds and then
resuspended with the addition of 4 mL of DMEM. Cells were taken from two 80%
confluent flasks. Cells were then put into a 15 mL conical tube and spun down to
form a pellet. The media was siphoned off, and the cells were resuspended in 1
mL of DMEM. The cell suspension was then added to the bioink, pipetted into a
Corning six-well plate and incubated for 30 minutes for 30 mg/mL and 60 minutes
for 15 mg/mL 4 mL DMEM was then pipetted dropwise onto the gels, which were
then incubated at 37 °C for six days. Cell survival and proliferation were then
observed. Cells exhibited a healthy morphology within the bioink. There was no
observable difference between the 15 mg/mL and 30 mg/mL concentration
bioinks. Upper layers of the bioink were found to be subject to fungal
contamination. The experiment was repeated a second time with the same
results. A third repeat of the experiment was conducted; however, flasks were
used in place of plates; fungal contamination was not observed. Ultimately, 30
mg/mL MTGase with 2% porcine gelatin in 10% PBS was selected as the best
candidate bioink (Figure 15).

Syringe Loading and Tip Optimization

26

Commercial bioprinters use an
extrusion tip of around 20 gauge. The
higher the gauge, the finer the tip -- and
consequently the higher the printing
resolution (Dharmadasa, 2016). The
finer the tip, the higher the shear stress
for the cells, resulting in an increase in
cell mortality. The pneumatic system
employed by commercial bioprinters

Figure 14: 5ml Disposable Syringes.

helps compensate for this by direct control of extrusion pressure. This approach
unfortunately also results in a higher incidence of tip clogging. For the sake of
this project, larger tips were selected to compensate for the pressure control
issues of the simpler screw drive. Stainless steel tips of 13- and 16-gauge were
selected as they were already on hand and produced extrusions of suitable
resolution for basic fabrication (Figure 14).
For tip optimization, the 3T3 cell-laden bioink was extruded in concentric
circles into six-well polystyrene plates. After the addition of 2 mL of bioink into
each well for both 13- and 16-gauge syringe tips, two other wells were filled with
bioink from an untipped syringe to act as a control. The wells were then filled
dropwise with 4 mL of DMEM media. Cells were incubated at 37 °C for six days.
Later syringe tip optimization investigated finer-gauge syringe tips as
printer instability issues were resolved during the PSP3 printhead trials. Stainless
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steel syringe tips were purchased and tested ranging from 12 - 28 gauge. These
tips are commonly available at hobby stores as they are used for precision
adhesive applications. Tip optimization was then performed again this time
investigating 18 and 20-gauge syringe tips. 20-gauge, 1-inch tips were
determined optimal as they allowed for extrusion of the higher viscosity bioink
necessary for print integrity while maximizing cell viability. 20-gauge also closely
matches the printer’s factory 26-gauge print tip extrusion size, eliminating the
need for factory software modification. The easily available, low-cost, stainless
steel luer lock fitting and factory-cut, 1-inch length made these adhesiveapplying syringe tips ideal for this project.
The initial protocol developed for syringe loading involved intermixing the
gelatin and enzyme and allowing incubation for three hours at 37 °C, followed by
intermixing the bioink with 3T3 cells resuspended in DMEM. The mixture was
then drawn into 5 mL disposable syringes and placed into a Pyrex petri dish for
an additional hour until reaching a semi-viscous state. The extrusion tips were
then attached to the disposal syringes.
Later, syringe tip assembly and system sterilization protocols were
optimized. Sterilization of the printer platform and exposed surfaces applied 70%
ethanol spray while male and female luer locks, the printing syringe tip, and
polyvinyl tubing all required submersion in 70% ethyl alcohol. These components
were then flushed via syringe with additional alcohol to ensure there were no
internal air pockets. After approximately one-hour submersion (i.e. the time
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required for the sterilized printer hardware to dry to the point of safe system
power-up) the submerged components were then assembled and flushed with 20
mL of sterile DMEM to ensure no remaining alcohol was present in the assembly.
This sterilization protocol was chosen as it did not require the use of an autoclave
and as such would greatly reduce the secondary equipment cost of the printing
system, allowing it to be more accessible to underfunded facilities.
The optimized bioink mentioned earlier was then loaded into the
disposable syringes and relocked to the alcohol-sterilized and DMEM-flushed
print tip assembly. Bioink was then extruded, flushing out any remaining inline
DMEM. The loaded printhead assembly was then allowed to air incubate for 45
minutes, or until bioink reached sufficient viscosity that syringe air bubbles could
not migrate when the syringe was inverted. Room temperature bioink incubation
proved to greatly cell-laden bioink gelation time from the original 3 hours at 37 °C
protocol down to 45 minutes while also reducing the possibility of accidental
contamination.
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CHAPTER THREE
PROJECT DATA

Optimization Data
Initial experiments with bioink in DMEM displayed repeated and prolific
contamination with gram positive bacilli bacteria. The source of contamination
was determined to be MooGloo MTGase, after incubation confirmed that both
gel, DMEM, and gel plus DMEM displayed no contamination.
The experiment was repeated with a new supply of MooGloo, with results
showing MTGase wells as contaminated but DMEM and gel controls as
uncontaminated. A method was then developed for enzyme solution filtration to
eliminate the bacterial contamination.

Well A 2: DMEM
+ Gelatin =
Uncontaminated

Well A 2: DMEM =
Uncontaminated

Well A 3: DMEM
+ MTGase =
Contaminated

Well B 1: DMEM
+ Bio ink +
10min UV =
Contaminated

Well B 2: DMEM
+ Bio ink +
20min UV =
Contaminated

Well B 3: DMEM
+ Bio ink +
30min UV =
Contaminated

Figure 15: Bioink Sterilization Optimization.
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Preliminary experiments with 3T3 cells in the presence of the bioink
showed no sign of retardation in growth rate or of abnormal morphology, for both
the 30 mg/mL and the 15 mg/mL MTGase concentrations. Congealed 15 mg/mL
and 30 mg/mL bioink was added into two-day-old flasks of 3T3 cells. Flasks were
cultured for an additional two days at 37 °C. Cells not only formed a confluent
layer on the flask, but they began to colonize the bioink fragments (Figure 13).
When cells were removed from their culture flask by trypsinization and
integrated into the bioink, the cells took on a new morphology. Cells on surface
layers of the bioink showed a spread similar to the morphology of 3T3 cells in 2D
culture. However, cells embedded in the bioink maintained a suspension
Day 2

Day 4

15 mg/mL

30 mg/mL

Figure 16: 3T3 Cells in Bioink.
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morphology. The cells did not stretch out and remained spherical. After seven
days in incubation, networks of fungal hyphae began to spread out from surface
layers of the bioink. The fungal contamination was present on both the 15 mg/mL
and 30 mg/mL MTGase conditions, but not in the 3T3 cell culture flasks. As there
was no observed difference in cell proliferation or morphology between the
15 mg/mL and 30 mg/mL MTGase conditions, the 30 mg/mL MTGase
concentration was selected as it congealed in less time (Table 2). The
experiment was duplicate, with the same results. For the next experiment, bioink
and cells were extruded into cell culture flasks in addition to a six-well plate. The
flask bioinks did not result in fungal contamination, while the six-well bioinks did
result in fungal contamination. This indicated that the fungal contamination was
likely related to laboratory, and incubator sterility issues (Figure 15).
Next, extrusion tip optimization was performed with untipped, 13-gauge,
and 16-gauge extrusions. The 30 mg/mL 3T3 cell-embedded bioink was extruded

Table 2: Syringe Tip and MTGase Concentration Optimization.
MTGase

0Gauge

15mg/ml

30mg/ml

13Gauge

18Gauge

20Gauge

24Gauge

Unstable/ Unstable/

Unstable/ Unstable/

Unstable/

Unstable/

Survived

Survived

Survived

Survived

Survived

Survived

Low Res/ Low Res/

Low Res/

Low Res/

Hi Res/

Hi Res/

Survived

Survived

Survived

Survived

Survived

Survived

16Gauge
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cultured and stored for all future work. The
GFP 3T3 variant line was chosen as live
cells produce the green fluorescence
protein and prior research indicated that
3T3 cells proliferate on the bioink surface in
a similar fashion as on a conventional
polystyrene petri dish. However, embedded
cells appeared to maintain a suspended
morphology. Whether these cells were still
alive and whether they would be able to

Figure 17: GFP 3T3 Cells in
Optimized Bioink.

proliferate and expand within a 3D printed
bioink construct remained unknown. Utilizing the GFP 3T3 cell line (Figure 17)
enabled distinguishing between living embedded cells and dead cells.
Repeating the optimization experiments demonstrated that embedded
cells survive the extrusion process with the 16-gauge syringe tip, as well as with
the 18- and 24-gauge tips. However, during the printing process the 15 mg/mL
MTGase concentration was deemed unusable as it had not provided sufficient
viscosity for the simple 1 cm ring-printing tests during the PSP2 printhead trials.
The 30 mg/mL concentration when combined with the 20-gauge syringe tip
represented the minimum viscosity and syringe tip gauge required to print
successfully 1 cm bioink rings. Finer gauge or higher viscosity prints were
deemed infeasible with the existing hardware as motor overheat became an
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2% Porcine
gelatin 55°C
incubation

30 mg/mL
MTGase
Centrifugation

Syringe Loading
Gelation & Printing

Filter
sterilization

GFP 3T3 Cells
1.83x107/ml

Figure 18: Bioink Processing Procedure.
apparent issue. A 20-gauge syringe tip with 30 mg/mL concentration comprised
the minimum requirement for stable, adequate resolution bioprinting as well as
the upper limit of the current hardware’s extrusion capabilities. This combination
of print tip and bioink formulation was chosen for testing with both the simple 1
cm ring-printing tests as well as the eventual, more complicated ear-printing
tests.
Test rings were printed as a method for optimizing printer hardware
configuration as well as for fine tuning printer software settings. The 3D models
were imported into the native factory slicing software FlashPrint developed for
use with the Creator Pro series desktop 3D printers. 3D models could easily be
manipulated in this software environment while print settings such as build
speed, printhead deposition rate, and infill could be adjusted and reported
directly to the printer (Figure 6). These features greatly simplified the process of
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system and model optimization. Although printhead and bioink viscosity
formulations were optimized by looking at cell survival, ultimately, they
represented the mechanical limits of the system (i.e. the best resolution and
material integrity that could be printed without overtaxing the printer’s extrusion
stepper motors).
Cell survival was compared between extruded and non-extruded bioinks
to find parameters that yielded sufficient survival. GFP 3T3 cells were later
investigated to obtain a better understanding of embedded cell survival within the
3D printed constructs. GFP cells were chosen for assessing cell survival and
proliferation as conventional staining methods like tryphan blue are toxic to cell
survival and would likely require multiple constructs to be produced and cross
sectioned over time. Alternatively, cell tracking fluorescent probes such as
thermofisher’s CellTracker Blue CMAC allows for live cell tracking over time, with
a portion of the probes being transferred over several cell divisions, however this
method is costly with the least expensive probe being 270$ for 5 mL.
Additionally, it was unknown if complications would arise, such as reduced cell
count accuracy as each generations probe concertation decreased, or if the
probes function would be effected by the presence of the MTGase.

Final Project Data
The final experiment investigated cell survival and proliferation between
extruded and non-extruded GFP 3T3 cell-laden bioinks. The bioprinter and
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Figure 19: ImageXpress Z-Stack Well Locations Diagram.

extrusion assembly sterilization protocol as stated in previous sections was
conducted. 3T3 GFP second passage cells were cultured and integrated with the
bioink at a concentration of 1.83x107/mL at a ratio of 95% living cells. 5 mL of
cell-infused bioink was loaded into a syringe for printing purposes (Figure 18).
The remaining 5 mL was transferred into a 6-well plate. The printer
incubated the bioink at room temperature for 45 minutes until printing viscosity
was reached, then bioink was deposited by the bioprinter at a rate of 1 mL per 10
minutes. The resulting ear was completed after 50 minutes. Once the ear was
completed, it was removed using a sterile spatula and placed in the 6-well plate.
Both the bio printed ear and non-extruded bioink was then submerged in 10 mL
of DMEM media with 20% serum as recommended by the cell line manufacturer.
The 6-well plate was then cultured for 17 days under standard mammalian tissue
culturing conditions. Cell survival was assessed via GFP cell counting with
ImageJ. Specific locations were imaged repeatedly over the 17-day period at 3-
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day

Figure 20: ImageJ Z-Stack Cell Counting Macro.

intervals with the use of ImageXpress micro-robotic microscope system by
Molecular Devices. 5 separate locations for both the unprinted bioink control and
the printed construct were selected (Figure 19). Each location had 15 images
taken on different focal planes. Each location and focal plane were then
reimaged via a computerized imaging protocol on subsequent days. All resulting
GFP images were then analyzed by ImageJ to create Z-stacks for each location
(Figure 20). These image stacks were then subdivided into three zones -bottom, middle, and top. Each Z-stack was then analyzed via a custom cellcounting macro created for ImageJ by Terisa Ubina (Bournias-V. lab). Resulting
data was then exported into a spreadsheet for analysis.
Previous experiments demonstrated that the optimized bioink was
sufficiently biocompatible as to allow 3T3 cell proliferation from within extruded
constructs however they did not track cell counts over time or compare cell
survival at relative depths within the bioink material.
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The initial cell counts between the extruded bioink and the non-extruded
control bioink had a noteworthy difference in initial cell concentrations. This
difference was likely due to settling of cells in the bioink prior to pipetting, with the
extruded bioink having on average 40 to 50 more cells in the 20x viewing area of
the microscope. Unprinted bioink had only a modest average increase in cell
count from day 3 to day 6, with an overall decreasing trend in living cell counts
after day 9 (Figure 21). Printed bioink, however, demonstrated overall GFP cell
proliferation until day 9 when cell counts declined. The trends in both the
experimental and control group were obtained by averaging each of the three
depth zones. Similar trends were found in both the bottom (Figure 22) and the
middle zones (Figure 23) when analyzed individually in either group. However,
the experimental top zone average cell count displayed a reduction in living GFP
cells between day 3 and day 6, with cell proliferation increasing in the view field
between days 6 and 9. Cell loss was also less pronounced between days 9 and
17 than during prior periods. Cells for experimental bottom and middle zones had
the greatest GFP density, likely indicating a greater cell density. However,
between days 12 and 15 the average cell loss in these zones outpaced the top
zone. Top zone averages for the experimental group had an average GFP cell
count of 80 cells in the visible area, with middle and bottom zones averaging
between 70 and 75 GFP cells in the visible field (Figure 24). Extruded control
cells followed a more consistent decline than their experimental counterparts
while middle zone cells between day 12 and day 15 rebounded with an average
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Figure 21: Average Cell Differential Count Experiment Vs Control.

Figure 22: Average Bottom Cell Differential Count Experiment Vs Control.
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Figure 23: Average Middle Cell Differential Count Experiment Vs Control.

Figure 24: Average Top Cell Differential Count Experiment Vs Control.
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cell count ranging between 35 and 40 versus bottom and upper zones with an
average cell count between 30 and 35.
The ear was cross-sectioned on day 17 prior to data-analyzing GFP cell
dispersal. Surface layers of the ear displayed 3T3 GFP cells confluent at several
layers deep. Bottom layers also displayed strong GFP, indicating high cell
counts. Middle sections of the ear displayed clusters of cells with strong GFP;
however, there were also large empty spaces between cell clusters. The clusters
themselves could indicate cell expansion, as cells were likely originally evenly
dispersed during the printing process.
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CHAPTER FOUR
DISCUSSION AND FUTURE WORK

Discussion
The project achieved several of its primary goals in that it represents the
lowest-cost bioprinter currently available. All components for this printer are
commercially available and require only basic tools to modify and construct. The
protocols developed over the past year afford any under-funded and or underequipped lab the opportunity to investigate bioprinting with a sterile hood and
basic bench-top centrifuge being the only major pieces of equipment. The
protocols were also developed with material cost in mind, the bioink formulation
and sterilization requiring low-cost, readily available materials such as syringe
filters, disposable syringes, ethanol, MTGase, and porcine gelatin. The quality of
the bioprinter itself would likely be considered introductory by current industry
standards with its limited bioink pressure control. Ultimately the printer represents
the most cost-effective, adaptable, and versatile system in that it has been
developed using open-source components and software, with underfunded
STEM student focused school laboratories in mind.
The system is of course not without its limitations. Due to instability, stable
direct injection was never achieved, resulting in additional sterilization steps and
a decrease in the system’s printable viscosity range. Without pressure control
during bioink injection, cultured cells likely experience a range of undefined
mechanical stresses during injection, which may affect cell differentiation and
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propagation. Mechanical stresses that the cells are exposed to during the printing
process vary from print to print as temperature, humidity, starting bioink viscosity,
and print duration have the potential to change the compressive and sheer stress
profile the cells are exposed to during the printing process.
One obvious issue during the final experiment was cell dispersal variation
in the bioink itself. As the cells settled in the bioink, there was a large
discrepancy between the unprinted control bioink and the printed bioink. This
variation was likely found in the prints themselves with the lower layers having
higher initial cell counts in a gradient from the initial layers of the bio printed
construct to the final upper layers. Indeed, this effect was indicated in the data
with the lower and middle layers having a greater initial GFP density on average
than the upper layer. Ideally, a multi-injection tip would be utilized to minimize
this effect, with bioink and cells being intermixed during the printing process. This
approach would allow for smoother cell distribution while permitting the cells to
be kept in the cell-friendly environment of a bioreactor until they are needed, thus
improving cell viability. Earlier attempts to use the 3D printer’s heating elements
were unsuccessful as the 37 °C environment impeded initial gelation of the
bioink.

Future Work
This project did not pursue several important avenues of investigation.
Defining the mechanical forces, the cells are exposed to in both the pre and post
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printing environment. Quantitative measurements of these mechanical stresses
and better control of environmental and procedural variables could be potentially
used to further optimize and differentiate bioink formulations for specific stem cell
line applications.
Additional modifications to the printer could also be pursued. With a
combination of Arduino controlled leveling stepper motors and optical positioning
sensors, the build platform could be automatically leveled during the printing
process potentially further improving print quality. Piezoelectric sensors could be
implemented to monitor bioink pressure in the current system allowing for bioink
injection pressures to be maintained within a predefined range, reducing the
potential variation in mechanical stresses cells are exposed to during the printing
process.
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APPENDIX A
AVERAGE CELL COUNT DATA GRAPHS
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Total average cell count graph depicting printed 3T3 GFP cell laden bioink vs
unprinted control over 17 days culturing. Cell counts calculated from fluorescent
20x ImageXpress Images using ImageJ cell count algorithm.

Average cell count graph depicting printed 3T3 GFP cell laden bioink vs
unprinted control over 17 days culturing. Cell counts calculated from fluorescent
20x ImageXpress Images captured at bottom layers.
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Average cell count graph depicting printed 3T3 GFP cell laden bioink vs
unprinted control over 17 days culturing. Cell counts calculated from fluorescent
20x ImageXpress Images captured at middle layers.

Average cell count graph depicting printed 3T3 GFP cell laden bioink vs
unprinted control over 17 days culturing. Cell counts calculated from fluorescent
20x ImageXpress Images captured at top layers.
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Average cell count graph depicting printed 3T3 GFP cell laden bioink over 17
days culturing. Cell counts calculated from fluorescent 20x ImageXpress Images
captured at bottom, middle and top layers.

Average cell count graph depicting unprinted control over 17 days culturing. Cell
counts calculated from fluorescent 20x ImageXpress Images captured at bottom,
middle and top layers.
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APPENDIX B
IMAGEXPRESS AND IMAGEJ DATA
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Cell count data for printed 3T3 GFP cell laden bioink vs unprinted control over 17
days culturing. Cell counts calculated from fluorescent 20x ImageXpress Images
using ImageJ cell count algorithm.
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3 AVG W2
44.4 SUM
bw2s2
49
10 119 BC
46.4 BC
bw2s3
40
33
34 MC
39.8 MC
bw2s4
84
117
48 TC
47 TC
bw2s5
56
36
31
w1s1
112
116 113 AVG W1
108.4 SUM
w1s2
118
149 128 BC
112.4 BC
w1s3
82
70
73 MC
109 MC
w1s4
130
122 118 TC
103.8 TC
w1s5
120
88
87
w2s1
107
104
93 AVG W2 64.2667 SUM
w2s2
70
50
55 BC
65 BC
w2s3
53
64
59 MC
63 MC
w2s4
36
57
58 TC
64.8 TC
w2s5
59
40
59
92818 BC
MC
TC
bw1s1
4
53
28 AVG W1 28.8667 SUM
bw1s2
0
0
0 BC
25.8 BC
bw1s3
51
53
55 MC
35.2 MC
bw1s4
0
0
0 TC
25.6 TC
bw1s5
74
70
45
bw2s1
83
67
50 AVG W2 51.4667 SUM
bw2s2
29
4
75 BC
47.2 BC
bw2s3
28
29
32 MC
49.2 MC
bw2s4
72
113
95 TC
58 TC
bw2s5
24
33
38
w1s1
61
103
56 AVG W1
96.2 SUM
w1s2
161
126 113 BC
102 BC
w1s3
78
72
69 MC
99.6 MC
w1s4
119
100 110 TC
87 TC
w1s5
91
97
87
w2s1
77
75 102 AVG W2 54.6667 SUM
w2s2
58
54
49 BC
55.4 BC
w2s3
46
49
42 MC
52.4 MC
w2s4
48
42
47 TC
56.2 TC
w2s5
48
42
41

51

W1

961
414
222
325

S DEV W1 54.199982
BC
46.072769
MC
46.784613
TC
71.042241

W2

666
232
199
235

S DEV W2 37.230556
BC
29.313819
MC
45.449972
TC
43.433858

W1

1626
562
545
519

S DEV W1 22.980737
BC
18.187908
MC
30.740852
TC
22.928149

W2

964
325
315
324

S DEV W2 21.116908
BC
26.504717
MC
24.576411
TC
15.84929

W1

433
129
176
128

S DEV W1 29.210729
BC
34.513765
MC
32.874002
TC
25.284383

W2

772
236
246
290

S DEV W2 30.895831
BC
27.994642
MC
42.133122
TC
26.448062

W1

1443
510
498
435

S DEV W1 27.728789
BC
39.204592
MC
19.21718
TC
24.94995

W2

820
277
262
281

S DEV W2 17.15337
BC
12.953764
MC
13.612494
TC
25.820534

100118 BC
MC
TC
bw1s1
72
0
0 AVG W1
bw1s2
4
33
32 BC
bw1s3
71
83
73 MC
bw1s4
31
10
14 TC
bw1s5
56
69
57
bw2s1
17
83 109 AVG W2
bw2s2
68
15
63 BC
bw2s3
35
30
32 MC
bw2s4
1
0
0 TC
bw2s5
17
12
23
w1s1
111
87
60 AVG W1
w1s2
127
141 119 BC
w1s3
76
49
58 MC
w1s4
92
66
81 TC
w1s5
85
99 110
w2s1
50
50
45 AVG W2
w2s2
26
32
32 BC
w2s3
38
34
30 MC
w2s4
31
34
38 TC
w2s5
27
30
33

40.3333
46.8
39
35.2

SUM W1
BC
MC
TC

605
234
195
176

S DEV W1 29.968237
BC
29.09811
MC
36.173194
TC
30.011664

33.6667
27.6
28
45.4

SUM W2
BC
MC
TC

505
138
140
227

S DEV W2 32.71886
BC
25.58906
MC
32.549962
TC
42.122441

90.7333
98.2
88.4
85.6

SUM W1
BC
MC
TC

1361
491
442
428

S DEV W1 27.019746
BC
20.608251
MC
35.125489
TC
28.058867

35.3333
34.4
36
35.6

SUM W2
BC
MC
TC

530
172
180
178

S DEV W2 7.5655862
BC
9.9146356
MC
8
TC
6.0249481

W1

670
222
191
257

S DEV W1 35.519947
BC
43.489079
MC
35.202273
TC
34.29723

W2

441
147
116
178

S DEV W2 19.791051
BC
17.980545
MC
8.4380092
TC
29.66985

W1

1133
370
360
403

S DEV W1 29.947255
BC
34.036745
MC
31.921779
TC
30.179463

W2

503
158
187
158

S DEV W2 8.9272189
BC
12.641202
MC
6.8410526
TC
6.6558245

100418 BC
MC
TC
bw1s1
103
10
9 AVG W1 44.6667 SUM
bw1s2
2
1
99 BC
44.4 BC
bw1s3
40
30
42 MC
38.2 MC
bw1s4
5
76
37 TC
51.4 TC
bw1s5
72
74
70
bw2s1
57
31
87 AVG W2
29.4 SUM
bw2s2
33
27
26 BC
29.4 BC
bw2s3
22
26
28 MC
23.2 MC
bw2s4
8
9
10 TC
35.6 TC
bw2s5
27
23
27
w1s1
17
17
33 AVG W1 75.5333 SUM
w1s2
92
97
90 BC
74 BC
w1s3
68
73
74 MC
72 MC
w1s4
94
88
92 TC
80.6 TC
w1s5
99
85 114
w2s1
10
45
23 AVG W2 33.5333 SUM
w2s2
33
41
40 BC
31.6 BC
w2s3
37
27
28 MC
37.4 MC
w2s4
43
39
36 TC
31.6 TC
w2s5
35
35
31
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